Bremelanotide (PT-141): What the Evidence Actually Shows

Bremelanotide activates melanocortin receptors without selecting between them, binding MC1R and MC4R most strongly at therapeutic doses. MC4R sits on neurons throughout the central nervous system, and the central-nervous-system route is what distinguishes this drug from the erectile-dysfunction pills: those act on blood vessels, this one acts on the brain. But the label declines to claim it knows how the effect happens, stating plainly that the mechanism by which the drug improves hypoactive sexual desire disorder in women is unknown. The second receptor is not incidental either. MC1R sits on melanocytes, and binding there produces melanin — which is why a drug taken for desire also darkens skin, and why the label carries a warning about pigmentation on the face, gums and breasts.¹

The approval rests on two identical 24-week randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women, and the results are best read alongside the endpoint that failed. On the desire questionnaire, the mean change from baseline was 0.5 against 0.2 on placebo in one trial and 0.6 against 0.2 in the other, on a scale running from 1.2 to 6.0. On the distress question — how often the woman felt bothered by low sexual desire, scored 0 to 4 — the mean change was minus 0.7 against minus 0.4 in both. Both differences were statistically significant. The number of satisfying sexual events, a secondary endpoint, did not differ from placebo in either trial: p equals 0.76 and 0.70, with a median change of zero in every arm. In men, the picture is different in kind. There is no registered trial of bremelanotide for erectile dysfunction at any phase, while the same registry search run for sildenafil in the same condition returns 104 studies, so the absence is not a broken query. What exists in men is four published randomized studies, all between 2004 and 2008, three of them small pharmacodynamic experiments measuring penile rigidity in a laboratory after an intranasal or subcutaneous dose — one of which enrolled 19 patients. The fourth, and the only one of any size, reported that 342 men who had not responded to sildenafil did better on intranasal bremelanotide; the Journal of Urology published an expression of concern about that paper in 2023.^1,3,4,5,6,7

The approved dosing is unusually specific, and worth knowing because compounded versions are not bound by it. One 1.75 mg subcutaneous injection into the abdomen or thigh, at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and no more than eight doses in a month — the label caps the monthly total because few patients in the phase 3 program exceeded it and because more frequent dosing raises the risk of pigmentation and lengthens the time each month spent with raised blood pressure. It also tells prescribers to stop after eight weeks if the patient reports no improvement. Nothing in the randomized record establishes a dose for a man. The male studies used intranasal sprays at 7 to 10 mg and subcutaneous doses from 0.3 to 10 mg, in single-dose or short crossover designs run two decades ago, and the intranasal formulation those doses belong to was never approved for anything. A dose that produced a measurable erection in a laboratory over one afternoon is not a schedule, and this page does not tell anyone what to take.^1,3,5

For the approved product the safety data are substantial and unflattering, which is a useful combination. Nausea was reported by 40% of treated patients against 1% on placebo, required anti-emetic treatment in 13%, and drove 8% out of the trials; a later study found that pre-treating with ondansetron did not reduce it. Flushing affected 20%, headache 11%, vomiting 5%. Overall, 18% of treated patients discontinued because of adverse reactions against 2% on placebo. Focal hyperpigmentation — including the face, gums and breasts — was reported by 1% of patients taking up to eight doses a month, but in a study that dosed daily for eight days it appeared in 38%, with a further 14% developing new pigment changes over eight more days, and resolution after stopping was not confirmed in every patient. Each dose transiently raises blood pressure by up to 6 mmHg systolic and slows the heart, peaking two to four hours in and usually settling within twelve; the drug is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended for anyone at high cardiovascular risk. One case of acute hepatitis was reported in the open-label extension. All of that was measured in premenopausal women taking a specific approved formulation two or three times a month. None of it was measured in men, and none of it was measured in a compounded preparation.^2,6,7